Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials
In >17,000 patients with HFmrEF/HFpEF, sustained SBP control during the first year (TIR 110–<130 mmHg) was associated with a lower subsequent risk of CV death or HF hospitalization, mainly driven by lower HF hospitalization.
- TIR captures sustained BP control that a single office reading may miss. It carried prognostic value beyond traditional risk factors.
- Existing medical therapies modestly increase TIR, and higher TIR is unlikely to fully explain their long-term benefit.
- These data support the importance of longitudinal BP control in HFmrEF/HFpEF aligned with current guidelines.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
